DebnathM, VenkatasubramanianG: Recent advances in psychoneuroimmunology relevant to schizophrenia therapeutics. Curr Opin Psychiatry, 26:433–439, 2013.
8.
DeutschSI, RosseRB, SchwartzBL, MastropaoloJ. A Revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol, 24:43–49, 2001.
9.
FallonBA, KeilpJG, CorberaKM, PetkovaE, BrittonCB, DwyerE, SlavovI, ChengJ, DobkinJ, NelsonDR, SackeimHA. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology, 70:992–1003, 2008.
10.
Gialdroni GrassiG, FietaA, SacchiF, DeroseV: Influence of ceftriaxone on natural defense systems. Am J Med, 77(4C):37–41, 1984.
11.
HornigM: The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness. Curr Opin Rheumatol, 25:488–795, 2013.
12.
KarakayaA, GümüşayS, YücesoyB, HengirmenS. Effect of short-term therapy with ceftizoxime and ceftriaxone on human peripheral WBC, serum immunoglobulins and lymphocyte subpopulations. Immunopharmacol Immunotoxicol, 17:775–781, 1995.
13.
KatoT, MizoguchiY, MonjiA, HorikawaH, SuzukiSO, SekiY, IwakiT, HashiokaS, KanbaS: Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. J. Neurochem, 105:815–825, 2008.
KirkpatrickB, MillerBJ: Inflammation and schizophrenia. Schizophrenic Bull. Epub ahead of print Sep26, 2013.
16.
Jimenez-ValeraM, MorenoE, Angeles AmatM, Ruiz-BravoA: Modification of mitogen-driven lymphoproliferation by ceftriaxone in normal and immunocompromised mice. Int J Antimicrobial Agents, 22:607–612, 2003.
17.
LjøstadU, MyglandA. Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors. Eur J Neurol, 17:118–123, 2010.
18.
MaesM, BerkM, GoehlerL, SongC, AndersonG, GałeckiP, LeonardB. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med. 10:66, 2012.
19.
MarkeljevićJ, SaracH, RadosM. Tremor, seizures and psychosis as presenting symptoms in a patient with chronic lyme neuroborreliosis (LNB). Coll Antropol, 35:313–318, 2011.
20.
MeloniF, BallabioP, BianchiL, GrassiFA, Gialdroni GrassiGG: Cefodizime modulates in vitro tumor necrosis factor-alpha, interleukin-6 and interleukin-8 release from human peripheral monocytes. Chemotherapy., 41:289–295, 1995.
21.
MelzerN, MeuthSG, Torres-SalazarD, BittnerS, ZozulyaAL, WeidenfellerC, KotsiariA, StangelM, FahlkeC, WiendlH:A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLoS One, 3:3149, 2008.
22.
MoonML, McNeilLK, FreundGG: Macrophages make me sick: How macrophage activation states influence sickness behavior. Psychoneuroendocrinol, 36:1431–1440, 2011.
23.
PachecoY, HosniR, DagrosaEE, GormandF, GuibertB, ChabannesB, LagardeM, Perrin-FayolleM: Antibiotics and production of granulocyte-macrophage colony-stimulating factor by human bronchial epithelial cells in vitro. A comparison of cefodizime and ceftriaxone. Arzneimittelforschung, 44:559–563, 1994.
24.
PfisterHW, Preac-MursicV, WilskeB, RiederG, FörderreutherS, SchmidtS, KapfhammerHP. Catatonic syndrome in acute severe encephalitis due to Borrelia burgdorferi infection. Neurology, 43:433–435, 1993.
25.
PfisterHW, Preac-MursicV, WilskeB, SchielkeE, SörgelF, EinhäuplKM. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis, 163:311–318, 1991.
26.
PfisterHW, RupprechtTA. Clinical aspects of neuroborreliosis and post-Lyme disease syndrome in adult patients. Int J Med Microbiol, 40:11–16, 2006.
27.
RoelckeU, BarnettW, Wilder-SmithE, SigmundD, HackeW. Untreated neuroborreliosis: Bannwarth's syndrome evolving into acute schizophrenia-like psychosis: A case report. J Neurol, 239:129–131, 1992.
